Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Neisseria meningitidis

Neisseria meningitidis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Neisseria meningitidis

22 trials tracked for Neisseria meningitidis: 13 in phase 3 or 4 and 1 with published results. The most-cited published study has 16 citations.

22Trials tracked
13Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 12 Phase 2 8 Other / NA 1
  1. Phase 3 Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) Completed · 16 cited
  2. Phase 4 Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine Completed
  3. Phase 3 Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Completed
  4. Phase 3 Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) Completed
  5. Phase 3 Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Completed
  6. Phase 3 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine Completed
Show 16 more trials
  1. Phase 3 Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia Completed
  2. Phase 3 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age Completed
  3. Phase 3 Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC Completed
  4. Phase 3 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. Completed
  5. Phase 3 Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants Completed
  6. Phase 3 Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines Completed
  7. Phase 3 Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB Completed
  8. Phase 2 Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine Completed
  9. Phase 2 Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine Completed
  10. Phase 2 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age Completed
  11. Phase 2 Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines Completed
  12. Phase 2 Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants Completed
  13. Phase 2 Dose Comparison Study of Menactra® in US Children Completed
  14. Phase 2 Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants Completed
  15. Phase 2 Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine Completed
  16. N/A Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Novel Antibiotic-Resistant Neisseria meningitidis Strain Detected in the United States
Infectious Disease
Novel Antibiotic-Resistant Neisseria meningitidis Strain Detected in the United States Health officials detect new antibiotic-resistant meningitis strain in the United States
A public health report describes the detection of a novel, antibiotic-resistant strain of Neisseria meningitidis in the United States.
Health officials detected a new antibiotic-resistant strain of meningitis bacteria in the United States that requires close monitoring.
CDC Apr 6, 2026